Clinical Trial Update: Durvalumab Plus Tremelimumab Combined With Proton Therapy for HNSCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating durvalumab plus tremelimumab with proton therapy for head and neck squamous cell carcinoma is reported as ongoing with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: Samsung Medical Center | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 2 | Status: UNKNOWN